Načítá se...
Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis C
Several direct‐acting antiviral agents (DAAs) have marketing authorization in Europe and in the USA and have changed the landscape of hepatitis C treatment: each DAA has its own metabolism and drug–drug interactions (DDIs), and managing them is a challenge. To compile the pharmacokinetics and DDI da...
Uloženo v:
| Vydáno v: | Br J Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5237698/ https://ncbi.nlm.nih.gov/pubmed/27530469 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13095 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|